Different classes of CB2 ligands potentially useful in the treatment of pain

Recent Patents on CNS Drug Discovery

Volumn 8, Issue 1, 2013, Pages 42-69

  Murineddu, Gabriele ^a   Deligia, Francesco ^a   Dore, Antonio ^a   Pinna, Giovanni ^a   Asproni, Battistina ^a   Pinna, Gerard A ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cannabinoid; CB2 receptor ligands; CB2 receptors; Chronic pain; Inflammatory pain; Neuropathic pain

Indexed keywords

AMIDE; ANALGESIC AGENT; AZETIDINE 2 CARBOXYLIC ACID; AZETIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID DERIVATIVE; DECAHYDROQUINOLINE DERIVATIVE; DIAZEPAM DERIVATIVE; IMIDAZOLE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; PROMETHAZINE; PURINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SULFONE DERIVATIVE; THIADIAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; UREA DERIVATIVE;

ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; HUMAN; INFLAMMATION; MIGRAINE; NEUROPATHIC PAIN; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL;

ANALGESICS, NON-NARCOTIC; ANIMALS; HUMANS; LIGANDS; MOLECULAR STRUCTURE; PAIN; PATENTS AS TOPIC; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875832800     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748898112079990016     Document Type: Article

References (129)

1. Calignano A, Giuffrida A, La Rana G, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-281.
2. Alvarez-Jaimes LJ, Palmer JA. The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation. Curr. Pharm. Biotechno. 2011; 12: 1644-1659.
3. Iversen L, Chapman V. Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2002; 2: 50-55.
4. Campbell FA, Tramer MR, Carroll D, Reynolds JM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 1-6.
5. 2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opinion Pharmac 2003; 3: 62-67.
6. Li J-X, Zhang Y. Emerging drug targets for pain treatment. Eur. J. Pharmacol. 2012; 681: 1-5.
7. Atwood BK, Straiker Alex, Mackie Ken. CB2: Therapeutic targetin-waiting. Prog. Neuropsychopharmacol. Biol. Psych. 2012; 38: 16-20.
8. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008; 153; 319-334.
9. Ibegbu AO, Mullaney I, Fyfe L, McBean D. Therapeutic potentials and uses of cannabinoid agonists in health and disease conditions. Br. J. Pharmacol. Toxicol. 2012; 3: 76-88.
10. Riether D. Selective cannabinoid receptor 2 modulators: a patent review 2009 - present, Expert Opin. Ther. Patents 2012; 22: 495-510.
11. Mackie K, Ross RA (Eds.). Special Issue: CB2 receptors. Br J Pharmacol 2008; 153; 177-401.
12. Beltramo M. Cannabinoid type 2 receptor as Target for Chronic Pain. Mini rev in Med Chem 2009; 9: 11-25.
13. 2 receptors in health and disease. Curr Med Chem 2010; 17: 1394-1410.
14. Frost, J.M., Latshaw, S.P., Dart, M.J., Carroll, W.A., Perez-Medrano, A., Kolasa, T., Patel, M.V., Nelson D., Li, T., Peddi, S., Wang, X., Liu, B. Thiazoles as cannabinoid receptor ligands. WO2010071783 (2010).
15. Carroll, W.A., Dart, M.J., Frost, J.M., Kolasa, T., Li, T., Liu, B., Perez-Medrano, A., Patel, M.V., Wang, X., Peddi, S. Novel compounds as cannabinoid receptor ligands. WO2010028338 (2010).
16. Kolasa, T., Frost, J.M., Patel, M.V., Latshaw, S.P., Perez-Medrano, A., Wang, X., Tietje, K.R.M., Peddi, S., Carroll, W.A. Compounds as cannabinoid receptor ligands. US8058293 (2011).
17. Kolasa, T., Frost, J.M., Patel, M.V., Latshaw, S.P., Perez-Medrano, A., Wang, X., Tietje, K.R.M., Peddi, S., Carroll, W.A. Novel compounds as cannabinoid receptor ligands. US8338467 (2012).
18. Frost, J.M., Latshaw, S.P., Dart, M.J., Carroll, W.A., Perez-Medrano, A., Kolasa, T., Patel, M.V., Nelson D.W., Li, T., Peddi, S., Wang, X., Liu, B. Novel compounds as cannabinoid receptor ligands. US20100216760 (2010).
19. Dart, M.J., Kolasa, T. Novel compounds as cannabinoid receptor ligands. WO20110306616 (2011).
20. Florjancic, A.S., Dart, M.J., Ryther, K.B., Perez-Medrano, A., Carroll, W.A., Patel, M.V., Tietje, K.R., Li, T., Kolasa, T., Gallagher, M.E., Peddi, S., Frost, J.M., Nelson, D.W. Novel compounds as cannabinoid receptor ligands and uses thereof. US20100093814 (2010).
21. Florjancic, A.S., Dart, M.J., Ryther, K.B., Perez-Medrano, A., Carroll, W.A., Patel, M.V., Tietje, K.R., Li, T., Kolasa, T., Gallagher, M.E., Peddi, S., Frost, J.M., Nelson, D.W. Novel compounds as cannabinoid receptor ligands and uses thereof. EP2222165 (2010).
22. Florjancic, A.S., Dart, M.J., Ryther, K.B., Perez-Medrano, A., Carroll, W.A., Patel, M.V., Tietje, K.R., Li, T., Kolasa, T., Gallagher, M.E., Peddi, S., Frost, J.M., Nelson, D.W. Novel compounds as cannabinoid receptor ligands and uses thereof. US7875639 (2011).
23. Kolasa, T., Frost, J.M., Patel, M.V., Latshaw, S.P., Perez-Medrano, A., Wang, X., Peddi, S., Carroll, W.A., Dart, M.J. Novel compounds as cannabinoid receptor ligands. US7875640 (2011).
24. Kolasa, T., Frost, J.M., Patel, M.V., Latshaw, S.P., Perez-Medrano, A., Wang, X., Peddi, S., Carroll, W.A., Dart, M.J. Novel compounds as cannabinoid receptor ligands. US20110086832 (2011).
25. Carroll, W.A., Dart, M.J., Li, T., Perez-Medrano, A., Peddi, S. Compound as cannabinoid receptor ligands and uses thereof. US8158663 (2012).
26. Carroll, W.A., Dart, M.J., Frost, J.M., Kolasa, T., Latshaw, S.P., Liu, B., Patel, M.Y., Perez-Medrano, A., Wang, X. Compound as cannabinoid receptor ligands. US8173687 (2012).
27. Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, et al. Characterization of a Cannabinoid CB2 Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-cyclopropanecarboxylic Acid [3-(2-Methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and Pharmacological Magnetic Resonance Imaging. J Pharmacol Exp Ther 2009; 328: 141-151.
28. 2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 2011; 162; 428-440.
29. 2 cannabinoid receptor agonists. Bioorg Med Chem Lett 2007; 17: 5133-5135.
30. 2 cannabinoid receptor agonists with good oral bioavailability. Bioorg Med Chem Lett 2007; 17: 6299-6304.
31. Carroll, W.A., Dart, M.J., Kolasa, T., Li, T., Nelson, D.W., Patel, M.V., Peddi, S., Perez-Medrano, A., Wang, X. Novel compounds as cannabinoid receptor ligands. US20100234345 (2010).
32. Carroll, W.A., Dart, M.J., Kolasa, T., Li, T., Nelson, D.W., Patel, M.V., Peddi, S., Perez-Medrano, A., Wang, X. Novel compounds as cannabinoid receptor ligands. US7872033 (2011).
33. Carroll, W.A., Dart, M.J., Kolasa, T., Li, T., Nelson, D.W., Patel, M.V., Peddi, S., Perez-Medrano, A., Wang, X. Novel compounds as cannabinoid receptor ligands. US20110082116 (2011).
34. Carroll, W.A., Kolasa, T., Li, T., Nelson, D.W., Patel, M.V., Peddi, S., Perez-Medrano, A., Wang, X. Novel compounds as cannabinoid receptor ligands. WO2010054024 (2010).
35. Carroll, W.A., Dart, M.J., Frost, J.M., Latshaw, S.P., Kolasa, T., Li, T., Peddi, S., Liu, B., Perez-Medrano, A., Patel, M.V., Wang, X., Nelson, D.W. Novel compounds as cannabinoid receptor ligands. WO2010033543 (2010).
36. Kolasa, T., Frost, J.M., Patel, M.V., Latshaw, S.P., Perez-Medrano, A., Wang, X., Tietje, K.R., Peddi, S., Carroll, W.A. Compounds as cannabinoid receptor ligands. EP2274306 (2011).
37. Wang, X., Frost, J.M., Dart, M.J., Liu, B. Compounds as cannabinoid receptor ligands. WO2010111573 (2010).
38. Wang, X., Frost, J.M., Dart, M.J., Liu, B. Compounds as cannabinoid receptor ligands. US20100249087 (2010).
39. Carroll, W.A., Dart, M.J., Frost, J.M., Latshaw, S.P., Li, T., Liu, B., Peddi, S., Wang, X., Kolasa, T., Nelson, D.W. Perez-Medrano, A. Compounds as cannabinoid receptor ligands. WO2010111572 (2010).
40. Carroll, W.A., Dart, M.J., Frost, J.M., Latshaw, S.P., Li, T., Liu, B., Peddi, S., Wang, X., Kolasa, T., Nelson, D.W., Perez-Medrano, A. Compounds as cannabinoid receptor ligands. US20100249129 (2010).
41. Wang, X., Dart, M.J., Liu, B. Compounds as cannabinoid receptor ligands. WO2010111574 (2010).
42. Wang, X., Dart, M.J., Liu, B. Compounds as cannabinoid receptor ligands. US8236822 (2012).
43. Carroll, W.A., Meyer, M.D., Perez-Medrano, A., Dart, M.J., Nelson, D.W. Novel compounds as cannabinoid receptor ligands. EP2219629 (2010).
44. Carroll, W.A. Combination therapy for reducing side effects using cannabinoid receptor ligands. EP2211860 (2010).
45. Carroll, W.A., Dart, M.J., Frost, J.M., Latshaw, S.P., Kolasa, T., Li, T., Peddi, S., Liu, B., Perez-Medrano, A., Patel, M., Wang, X., Nelson, D.W. Compounds as cannabinoid receptor ligands. US8188135 (2012).
46. Frost, J.M., Tietje, K.R., Dart, M.J., Meyer, M.D. Novel indoles are cannabinoid receptor ligands. US7750039 (2010).
47. Frost, J.M., Tietje, K.R., Dart, M.J., Meyer, M.D. Novel indoles are cannabinoid receptor ligands. US20110065685 (2011).
48. 2 Cannabinoid Receptor Activity. J Med Chem 2010; 53: 295-315.
49. Carroll, W.A., Dart, M.J., Perez-Medrano, A., Nelson. D. Novel compounds as cannabinoid receptor ligands. EP2176219 (2010).
50. Nelson, D., Frost, J.M. Novel compounds as cannabinoid receptor ligands. US7868038 (2011).
51. Nelson, D.W., Latshaw, S.P. Compounds as cannabinoid receptor ligands. US7985768 (2011).
52. Bartolozzi, A., Berry, A., Cirillo, P.F., Hickey, E.R., Riether, D., Wu, L., Zindell, R.M. Heterocyclic compounds which modulate the CB2 receptor. WO2010096371 (2010).
53. Hickey, E.R., Riether, D., Thomson, D.S., Wu, L., Zindell, R.M. Azetidine 2-carboxamide derivatives which modulate the CB2 receptor. US20120142666 (2012).
54. Hickey, E.R., Riether, D., Thomson, D.S., Wu, L., Zindell, R.M. Azetidine 2-carboxamide derivatives which modulate the CB2 receptor. WO2010147791 (2010).
55. Berry, A., Betageri, R., Hickhey, E.R., Someina, K., Riether, D., Wu, L., Zindell, R.M. Pyrrolidine compounds which modulate the CB2 receptor. US20120142677 (2012).
56. Berry, A., Betageri, R., Riether, D., Hickhey, E.R., Wu, L., Zindell, R.M. Pyrrolidine compounds which modulate the CB2 receptor. WO2010077836 (2010).
57. Bartolozzi, A., Berry, A., Cirillo, P.F., Hickey, E.R., Riether, D., Wu, L., Zindell, R.M. Heterocyclic compounds which modulate the CB2 receptor. US20110312944 (2011).
58. Berry, A., Riether, D., Zindell, R.M., Blumire, N.J. Compounds which modulate the CB2 receptor. US20100331304 (2010).
59. Berry, A., Cirillo, P.F., Hickey, E.R., Riether, D., Thomson, D., Zindell, R.M., Blumire, N.J., Chowdhury, C., Ermann, M., Jenkins, J.E., Mushi, I., Palmer, C.F., Taylor, M.Compounds which modulate the CB2 receptor. US7928123 (2011).
60. Bartolozzi, A., Riether, D., Zindell, R.M., Amouzegh, P., Blumire, N.J., Ermann, M., Mushi, I., Scott, R.J. Compounds which selectively modulate the CB2 receptor. US20110071196 (2011).
61. Regan, J., Riether, D. Sulfone compounds which modulate the CB2 receptor. US20110124696 (2011).
62. Regan, J., Riether, D. Sulfone compounds which modulate the CB2 receptor. US8178568 (2012).
63. Berry, A., Cirillo, P.F., Hickey, E.R., Riether, D., Thomson, D., Ermann, M., Jenkins, J.E., Mushi, I., Taylor, M., Chowdhury, C., Palmer, C.F., Blumire, N.J. Compounds which modulate the CB2 receptor. US20110071127 (2011).
64. Hickey, E.R., Riether, D., Thomson, D.S., Zindell, R.M., Amouzegh, P., Ermann, M., Palmer, C.F., Whittaker, M. Sulfone compounds which modulate the CB2 receptor. US20120015988 (2012).
65. Marx IE, DiMauro EF, Cheng A, Emkey R, Hitchcock SA, Huang L, et al. Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties. Bioorg Med Chem Lett 2009; 19: 31-35.
66. Cirillo, P.F., Hickey, E.R., Riether, D., Wu, L., Zindell, R.M., Amouzegh, P., Ermann, M., Walker, E.R. Diazepane compounds which modulate the CB2 receptor. US20100261708 (2010).
67. Berry, A., Cirillo, P.F., Hickey, E.R., Riether, D., Thomson, D.S., Wu, L. Compounds which modulate the CB2 receptor. US8173638 (2012).
68. Riether D, Wu L, Cirillo PF, Berry A, Walker ER, Ermann M, et al. 1,4-Diazepane compounds a s potent and selective CB2 agonists: Optimization of metabolic stability. Bioorg Med Chem Lett 2011; 21: 2011-2016.
69. Bartolozzi, A., Hichkey, E.R., Riether, D., Wu, L., Zindell, R.M., Blumire, N.J., Ermann, M., Glenn, E.T., Khor, S., Zawadzki, P. Compounds which selectively modulate the CB2 receptor. US20110136869 (2011).
70. Cirillo, P.F., Hickey, E.R., Riether, D., Ermann, M., Mushi, I. Amine and ether compounds which modulate the CB2 receptor. US20110190256 (2011).
71. Bartolozzi, A., Berry, A., Hichkey, E.R., Ostermeier, M., Riether, D., Sauer, A., Thomson, D.S., Wu, L., Zindell, R.M., Amouzegh, P., Blumire, N.J., East, S.P., Ermann, M., Khor, S., Mushi, I. Therapeutic uses of compounds which selectively modulate the CB2 receptor. US20110312932 (2011).
72. Bartolozzi, A., Berry, A., Hichkey, E.R., Ostermeier, M., Riether, D., Sauer, A., Thomson, D.S., Wu, L., Zindell, R.M., Amouzegh, P., Blumire, N.J., East, S.P., Ermann, M., Khor, S., Mushi, I. Therapeutic uses of compounds which selectively modulate the CB2 receptor. US8048899 (2012).
73. Riether, D., Zindell, R.M., Ermann, M., WO2011109324 (2011).
74. Ermann, M., Riether, D., Zindell, R.M. US20120071529 (2012).
75. O'Connor, S.J., Newcom, J.S., Ralbovsky, J.L., Gustafson, G.R., Beckett, R.P., Luo, R.Z. Substituted imidazoheterocycle derivatives. WO2010068520 (2010).
76. O'Connor, S.J., Newcom, J.S., Ralbovsky, J.L., Gustafson, G.R., Beckett, R.P., Luo, R.Z. Substituted imidazoheterocycle derivatives. US20120015930 (2012).
77. Beckett, R.P., Fpster, R., Henault, C., Ralbovsky, J.L., Gauss, C.M., Gustafson, G.R., Luo, R.Z., Campbell, A-M., Shelekin, T.E. Substituted imidazoheterocycles. US7517874 (2009).
78. Beckett, R.P., Fpster, R., Henault, C., Ralbovsky, J.L., Gauss, C.M., Gustafson, G.R., Luo, R.Z., Campbell, A-M., Shelekin, T.E., Zablocki, M-M.E. Uses of substituted imidazoheterocycles. US20110034443 (2011).
79. Luo, R.Z. Bicyclic pyrazolo-heterocycles. US7741350 (2010).
80. Luo, R.Z. Bicyclic pyrazolo-heterocycles. US8211926 (2012).
81. Luo, R.Z. Bicyclic pyrazolo-heterocycles. WO2010088050 (2010).
82. Luo, R.Z. Bicyclic pyrazolo-heterocycles. US20110275609 (2011).
83. Chang, C-P., Stalewski, J., Riviere, P.J.-M., Wesniewski, K.A., Schteingart, C.D. Amide or thioamide derivatives and their use in the treatment of pain. US7504538 (2009).
84. Chang, C-P., Stalewski, J., Riviere, P.J.-M., Wesniewski, K.A., Schteingart, C.D. Amide or thioamide derivatives and their use in the treatment of pain. US20100105777 (2010).
85. Newcom, J.S., Gauss, C.M., Gustafson, G.R. Benzo-fused heterocycles. US7960376 (2011).
86. Newcom, J.S., Gauss, C.M., Gustafson, G.R. Substituted pyridoxazines. US7960377 (2011).
87. Dolle, R.E., Worm, K., Zhou, Q.J. Phenyl derivatives and methods of use. US20100168108 (2010).
88. Goodman AJ, Ajello CW, Worm K, Le Bourdonnec B, Savolainen MA, O'Hare H, et al. CB2 selective sulfamoylbenzamides: Optimization of the amide functionality. Bioorg Med Chem Lett 2009; 19: 309-313.
89. Sellitto I, Le Bourdonnec B, Worm K, Goodman AJ, Savolainen MA, et al. Novel sulfamoylbenzamides as selective CB2 agonists with improved in vitro metabolic stability. Bioorg Med Chem Lett 2010; 20: 387-391.
90. Worm K, Weaver DG, Green RC, Saeui CT, Dulay D-MS, Barker WM, et al. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. Bioorg Med Chem Lett 2009; 19: 5004-5008.
91. Chu G-H, Saeui CT, Worm K, Weaver DG, Goodman AJ, Broadrup RL, et al. Novel pyridine derivatives as potent and selective CB2 cannabinoid agonists. Bioorg Med Chem Lett 2009; 19: 5931-5935.
92. Wu, Z., Hartnett, J.C. Substituted 1,2,4-oxadiazoles and analogs thereof as CB2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases. WO2009051705 (2009).
93. Wu, Z., Hartnett, J.C. Substituted 1,2,4-oxadiazoles and analogs thereof as CB2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases. US20100227845 (2010).
94. Wu, Z., Green, A.I., Hartnett, J.C. CB2 receptor ligands for the treatment of pain. WO2009025785 (2009).
95. Wu, Z., Green, A.I., Hartnett, J.C. CB2 receptor ligands for the treatment of pain. US20120004222 (2012).
96. Bilodeau, M.T., Burgey, C.S., Deng, Z.J., Kett, N.R., Melamed, J., Munson, P.M., Nanda, K.K., Thompson, W., Trotter, B.W., Wu, Z., Hartnett, J.C. Imidazopyridine analogs as CB2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases. US20090325936 (2009).
97. Bilodeau, M.T., Kett, N.R., Lindsley, C., Manley, P.J., Melamed, J., Paone, D.V., Wu, Z. Decahydroquinoline analogs as CB2 receptor modulators, useful in the treatment of pain, respiratory and nonrespiratory diseases. US20100099673 (2010).
98. Moore, B.M.II, Gurley, S., Mustafa, S. Furanopyrimidine cannabinoid compounds and related methods of use. US20110046163 (2011).
99. Moore, B.M.II, Gurley, S., Mustafa, S. Furanopyrimidine cannabinoid compounds and related methods of use. WO2011022694 (2011).
100. Moore, B.M.II, Gurley, S., Mustafa, S. Furanopyrimidine cannabinoid compounds and related methods of use. US20110046176 (2011).
101. Moore, B.M.II, Gurley, S., Mustafa, S. Furanopyrimidine cannabinoid compounds and related methods of use. WO2011022692 (2011).
102. Moore, B.M.II, Bhattacharjee, H., Yates, C.R., Stuart, L. Tri-arylheteroaromatic cannabinoids and use thereof. US7888365 (2011).
103. Moore, B.M.II, Bhattacharjee, H., Mustafa, S. Tri-arylheteroaromatic cannabinoids and use thereof. US20110207748 (2011).
104. Liu, C., Wrobleski, S., Leftheris, K., Wu, G., Sher, P.M., Ellsworth, B.A. Indoleindane amide compounds useful as CB2 agonists and method. WO2009015169 (2009).
105. Liu, C., Wrobleski, S., Leftheris, K., Wu, G., Sher, P.M., Ellsworth, B.A. Indoleindane amide compounds useful as CB2 agonists and method. US7943658 (2011).
106. Matsushima, Y., Kubota, H., Hamaguchi, H., Okamoto, Y., Hondo, T., Nishigaki, F. Pyrimidine compounds. US20110053912 (2011).
107. Mathuppalaniappan, M., Balasubramanian, G., Gullapalli, S., Khairatkar, J., Narayanan, S. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation. US7923465 (2011).
108. Mathuppalaniappan, M., Balasubramanian, G., Gullapalli, S., Joshi, N.K., Narayanan, S. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation. US20120142748 (2012).
109. Dietz, M., Gruener, S., Hebeisen, P., Meyer Reigner, S.C., Nettekoven, M., Puellmann, B., Roever, S., Ullmer, C. Pyrazine-2-carboxamide derivatives. EP2076499 (2010).
110. Harnett, J. 4-Phenyl-1,3-thiazoles and 4-phenyl-1,3-oxazoles derivatives as cannabinoid receptor ligands. US20110059970 (2011).
111. Sprott, K., Rohde, J., Nakai, T., Peng, B., Talley, J.J. CB receptor agonists. WO2011006066 (2011).
112. Rhode, J., Kim, C., Nakai, T. Cannabinoid receptor agonists. WO2011100324 (2011).
113. Rhode, J., Peng, B., Nakai, T., Sprott, K., Mermerian, A., Schairere, W.C. Cannabinoid agonists. WO2011100359 (2011).
114. Shankar, B.B., Gilbert, E., Rizvi, R.K., Huang, C., Kozlowsky, J.A., McCombie, S., Shih, N-Y. Cannabinoid receptor ligands. US7750158 (2010).
115. Attala, M.N., Diaz, P. Heterocyclic modulators of cannabinoid receptors. WO2009012221 (2009).
116. Osakada, N., Osahada, M., Sawada, T., Kaneko, S. Imidazole derivative. EP2090570 (2011).
117. Osakada, N., Osahada, M., Sawada, T., Kaneko, S., Mizutani, A., Uesaka, N., Nakasato, Y., Katayama, K., Sugawara, M., Kitamura, Y. Imidazole derivatives. US8273738 (2012).
118. Sawada, T., Osakada, N., Kaneko, S., Mizutani, A., Uesaka, N., Katayama, K. Fused heterocycle derivative. US8236841 (2012).
119. Olsson, R., Burstein, E., Knapp, A.E., Eskildsen, J., Castillo, J., Nairne, J., Morrison Iveson, V., Gibson, A. Imidazol [1,2-a]pyridines and related compounds with activity at cannabinoid CB2 receptors. US20110206607 (2011).
120. Ando, K., Iwata, Y. N-Substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity. US20110281840 (2011).
121. Gijsen, H.J.M., De Cleyn, M.A.J., Surkyn, M. Benzimidazole cannabinoid agonists. US8193369 (2012).
122. Ando, K., Kawai, M., Masuda, T., Omura, H. Benzimidazolone derivatives as CB2 receptor ligands. US8138177 (2012).
123. van der Stelt, M., Cals, J.M.G.B. 1-(Biphenyl-4-ylmethyl)imidazolidine-2,4-dione. US7960560 (2011).
124. van der Stelt, M., Cals, J.M.G.B., Clomp, J.P.G. 1-(4-(Pyridin-2-yl)benzyl)imidazolidine-2,4-dione. US8143246 (2012).
125. Blackburn, A.C., Han, S., Jones, R.M., Montalban, A.G., Pal, B.B., Rueter, J.K. Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators). WO2012116276 (2012).
126. Thatte, J., Blackburn, A.C., Han, S., Jones, R.M., Jung, J-K., Montalban, A.G., Pal, B.B., Rueter, J.K., Strah-Pleynet, S., Thorensen, L., Xiong, Y., Yue, D., Zhu, X. Cannabinoid receptor modulators. WO2012116279 (2012).
127. Jones, R.M., Han, S., Thorensen, L., Jung, J-K., Strah-Pleynet, S., Zhu, X., Xiong, Y., Yue, D., Cannabinoid receptor modulators. US20120214766 (2012).
128. Chen, J., Pettit, S.N., Fliri, H. Pyridazine derivatives useful as cannabinoid-2-agonists. WO2011097553 (2011).
129. Hollinshead, S.P. Purine compounds used as CB2 agonists. WO2011123482.